Navigation Links
Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
Date:4/9/2008

atient-years) for comparator-treated patients. There were too few cases to determine whether the emergence of these events is related to Exubera. All patients who were diagnosed with lung cancer had a prior history of cigarette smoking."

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled ten approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding management's plans and expectations for Nektar's business including the potential of its product pipeline. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) the Nektar's proprietary product candidates and those of certain of its partners are in the early phases of clinical development and pre-clinical development and the risk of failure is high and can unexpectedly occur at any stage, (ii) the timing or success of the commencement or conclusion of planned clinical trials is subject to a number of uncertainties including but not limited to clinical design, patient enrollment, regulatory requirements and clinical outcomes, (iii) Nektar's or its partner's success in meeting minimum clinical end points and obtaining regulatory approvals for product candidates, (iv) Nektar may not successfully complete new collaborative partnerships with respect to its product candidates, or if any partnerships Nektar does negotiate do not include sufficiently favorable commercial terms, Nektar may not receive
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
2. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
3. OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
4. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
5. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
6. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
7. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
8. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
9. Potential Early Warning System for Lung Cancer Identified
10. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
11. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... YORK , June 1, 2015   ... of Open, Transparent and Connected financial marketplaces for ... Incorporated, a San Diego -based ... traded on OTCQB®, America,s only public venture market ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ...
(Date:6/1/2015)... , June 1, 2015 /CNW Telbec/ -  Ergoresearch Ltd ... and known under the « Équilibre, orthèses et ... Ended on March 31, 2015. All dollar amounts in the ... for the third quarter of fiscal year 2015 ended this ... to revenues of $ 3,823,151 for the quarter ended March ...
(Date:6/1/2015)... Columbia and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a ... therapies in new orphan drug indications, announced that it ... live webcast today, June 1, 2015, at 5:30 p.m. ... data from its Phase I/II study of VAL-083 ...
Breaking Medicine Technology:OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 3Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 4DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 2DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 3DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 4
... Novartis Pharmaceuticals Corporation ("Novartis") announced today that ... Drugs Advisory Committee (ODAC) recommended approval of Afinitor® ... advanced neuroendocrine tumors (NET) of pancreatic origin. ... data from the everolimus RADIANT (RAD001 In Advanced ...
... 12, 2011 MSA (NYSE: MSA ), the ... that protect people,s health and safety, announced today that it ... via the Internet on Thursday, April 28, 2011 at 10:00 ... Investors and interested parties will have the opportunity ...
Cached Medicine Technology:Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10MSA Schedules First Quarter Earnings Webcast 2
(Date:6/2/2015)... Join us for a new event in Westwood, New Jersey—the ... , who overcame her brain aneurysm during the summer of ... awareness and funds for brain aneurysm research. , Rhonda ... will be one less case of someone suffering from a ... the 1st Anniversary Awareness Walk in Honor of Rhonda ...
(Date:6/2/2015)... Vancouver, B.C., Canada (PRWEB) June 02, 2015 ... publisher of audit, compliance and risk solutions ... a new online risk management effectiveness gap-improvement program. ... the effect of uncertainty on objectives. Organizations not ... they improve their capabilities to do this (risk ...
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Lynn Lester as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... exclusively for professional women, boasting more than 700,000 members ... to honor Lynn Lester with this prestigious award,” said ...
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Lourinda Willey as a 2015-2016 ... Circle. She is recognized with this prestigious distinction for ... is the nation’s leading networking organization exclusively for professional ... operating Local Chapters. , "I’m pleased to present Lourinda ...
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Selma Tansey as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... exclusively for professional women, boasting more than 700,000 members ... to present Selma with this important honor," said NAPW ...
Breaking Medicine News(10 mins):Health News:New Awareness Raising Event in Westwood, NJ to Benefit Renowned Brain Aneurysm Foundation 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Selma Tansey, Executive Director of Washington Communities Human Services, Into its VIP Professional Woman of the Year Circle 2
... in alpha-linoleic acid reduced cardiac events in Asian people at ... in South Asian people, especially if they move to the ... by conventional risk factors,// like diabetes and high blood pressure. ... with the effect of a Mediterranean type diet on cardiac ...
... to a major medical study by researchers it is ... The latest from researchers in Denmark, observe that people ... lesser risk of developing dementia and Alzheimer's disease. People ... benefit. ,The researchers are realistic about their research. ...
... than a placebo when it comes to the relief of ... at the Mayo Clinic, the majority of people with muscle ... relieved// by ionized bracelets. So the researchers divided the participants ... ionized bracelet, while the other received a placebo bracelet that ...
... doing exercise improves your cholesterol profile, even in the ... shown how exercise affects the level of 'good' and ... the body attached to protein molecules, the combination being ... (LDL or 'bad' cholesterol) are linked to heart disease, ...
... person aged 40 or over has a lifetime risk of ... they have high blood pressure. Heart failure is an increasing ... within the heart which makes it hard to pump blood ... the condition is very disabling. ,Researchers for the ...
... survival of criticare patients gets better if specialists in ... Hopkins and Pittsburgh University have analysed the evidence on ... found that patients do much better if they are ... in critical care medicine. ,Previous research has ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: